Literature DB >> 20506693

International stem cell tourism and the need for effective regulation. Part I: Stem cell tourism in Russia and India: clinical research, innovative treatment, or unproven hype?

Cynthia B Cohen1, Peter J Cohen.   

Abstract

Persons with serious and disabling medical conditions have traveled abroad in search of stem cell treatments in recent years. However, weak or nonexistent oversight systems in some countries provide insufficient patient protections against unproven stem cell treatments, raising concerns about exposure to harm and exploitation. The present article, the first of two, describes and analyzes stem cell tourism in Russia and India and addresses several scientific/medical, ethical, and policy issues raised by the provision of unproven stem cell-based treatments within them. The distinction between treatment based on proven clinical research and "innovative treatment" is addressed and the authors conclude that the innovations at issue constitute neither. Regulatory measures need to be developed or strengthened in accord with internationally accepted standards in such countries to protect those seeking stem cell treatments.

Entities:  

Mesh:

Year:  2010        PMID: 20506693     DOI: 10.1353/ken.0.0305

Source DB:  PubMed          Journal:  Kennedy Inst Ethics J        ISSN: 1054-6863


  11 in total

1.  Stem-cell tourism and scientific responsibility. Stem-cell researchers are in a unique position to curb the problem of stem-cell tourism.

Authors:  Zubin Master; David B Resnik
Journal:  EMBO Rep       Date:  2011-09-30       Impact factor: 8.807

2.  Gordie Howe's Stem Cell 'Miracle': A Qualitative Analysis of News Coverage and Readers' Comments in Newspapers and Sports Websites.

Authors:  Christen Rachul; Timothy Caulfield
Journal:  Stem Cell Rev Rep       Date:  2015-10       Impact factor: 5.739

3.  CORR® International - Asia-Pacific: Stem Cell-based Treatments in Orthopaedic Clinical Practice-Is it Ready For Primetime in the Asia-Pacific Region?

Authors:  Tae Kyun Kim
Journal:  Clin Orthop Relat Res       Date:  2019-04       Impact factor: 4.176

4.  The Shortage of Malaysian Stem Cell Ethics in Mainstream Database: a Preliminary Study.

Authors:  Gopalan Nishakanthi
Journal:  Asian Bioeth Rev       Date:  2019-11-28

Review 5.  Stem cell/cellular interventions in human spinal cord injury: Is it time to move from guidelines to regulations and legislations? Literature review and Spinal Cord Society position statement.

Authors:  Harvinder S Chhabra; Kanchan Sarda; Geeta Jotwani; M Gourie-Devi; Erkan Kaptanoglu; Susan Charlifue; S L Yadav; B Mohapatra; Abhishek Srivastava; Kedar Phadke
Journal:  Eur Spine J       Date:  2019-05-16       Impact factor: 3.134

Review 6.  What is the potential of oligodendrocyte progenitor cells to successfully treat human spinal cord injury?

Authors:  Robert A Watson; Trevor M Yeung
Journal:  BMC Neurol       Date:  2011-09-23       Impact factor: 2.474

7.  "I knew what was going to happen if I did nothing and so I was going to do something": faith, hope, and trust in the decisions of Canadians with multiple sclerosis to seek unproven interventions abroad.

Authors:  Jeremy Snyder; Krystyna Adams; Valorie A Crooks; David Whitehurst; Jennifer Vallee
Journal:  BMC Health Serv Res       Date:  2014-09-30       Impact factor: 2.655

8.  Governing stem cell therapy in India: regulatory vacuum or jurisdictional ambiguity?

Authors:  Shashank S Tiwari; Sujatha Raman
Journal:  New Genet Soc       Date:  2014-10-29

9.  The Challenge for Reconstructive Surgeons in the Twenty-First Century: Manufacturing Tissue-Engineered Solutions.

Authors:  Zita M Jessop; Sarah Al-Himdani; Marc Clement; Iain Stuart Whitaker
Journal:  Front Surg       Date:  2015-10-16

10.  Report: Stem cell applications in neurological practice, an expert group consensus appraisal.

Authors:  M Gourie Devi; Alka Sharma; Sujata Mohanty; Neeraj Jain; Kusum Verma; M Vasantha Padma; Pramod Pal; H S Chabbra; Satish Khadilkar; Sudesh Prabhakar; Gagandeep Singh
Journal:  Ann Indian Acad Neurol       Date:  2016 Jul-Sep       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.